Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
56 participants
OBSERVATIONAL
2025-03-31
2027-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
2. Correlate the expression levels of measured biomarkers to the pregnancy rate and live birth rate.
3. Correlate the expression levels of the measured biomarkers with the embryological outcome which is the oocyte maturity rate, fertilization rate, embryo cleavage rate and blastocyst formation rate and implantation rate.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Geneexpression as a Marker of Embryo Viability
NCT02399787
Follicular Fluid microRNAs in Ovarian Aging and Reproduction
NCT07214246
Establishing a Minimum Predictive Threshold Follicular Size and Oocyte Retrieval in ICSI Cycle
NCT07331493
Effectiveness of PGT-A: IVF Versus ICSI
NCT03708991
Outcomes of the Embryos of Different Ovarian Follicle Sizes, and the miRNA Detection in Their Blastocyst Culture
NCT05947526
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The success of the IVF process is conditioned by the receptivity of endometrium, the selection of a competent embryo for transfer, and the determination of the window of implantation (WOI). The biggest causes of the negative outcome of the IVF process are poor embryo quality and low endometrial receptivity.
The implantation capacity of a morphologically high-quality embryo reaches only 50%, and the success rate of IVF may therefore still not exceed 30%.
The increased interest in assisted reproduction through IVF leads to an urgent need to identify biomarkers that reliably highly predict the success of pregnancy.
The current paradox is that multiple embryo transfer that may leads to severe obstetric and perinatal complications seems to be the most valid measure to secure high success rate in the majority of clinic centers. Therefore, to avoid multiple transfer of embryos, it is urgent to explore biomarkers for IVF prognosis to select high-quality oocytes and embryos.
CircRNA, as a new class of non-coding RNA, exhibits high stability, abundance, and tissue specificity. It participates in the process of gene translation into protein and interacts with RNA binding protein through sponging miRNA or directly binding with RNA-binding proteins, and even translating into proteins.
Researchers have shown that circRNAs play important roles in cancer through the circRNA-miRNA-mRNA regulatory axis, thus affecting the occurrence and development of cancer. Many studies have shown that circRNAs can regulate the occurrence and development of different kinds of diseases.
CircRNA-mediated regulation in the ovary has drawn more and more attention recently , the biological functions of circRNAs in the ovary are still largely unknown. Liu et al. reported altered circular RNA expression in patients with recurrent implantation failure (RIF).
CircRNAs are commonly used as diagnostic and prognostic biomarkers. However, the exact role of circRNAs in implantation remains largely unknown.
Has-circ-0033392 is one of three key circRNAs were found to be mainly involved in the regulation of actin filament organization, focal adhesion, and cadherin binding.
Cadherins are a group of membrane proteins involved in cell adhesion, they assure adhesion between adjacent cells by the homotypic interactions of cells exposing similar sets of cadherins at their surfaces, cadherins contribute to tissue integrity, regulating cell migration, cell differentiation and the control size of a specific cell population, folliculogenesis strictly depends on the contact of the surrounding granulosa cells (GCs) and the oocyte.
Embryo implantation also involves the adhesion of trophoblast cells to the epithelial layer of the endometrium, dependent on cell-cell adhesion molecule interactions. However, so far, there is no research about has-circ-0033392 on diseases published.
MicroRNAs (miRNAs), a class of small non-coding RNAs with -22 nucleotides in length, regulate a wide array of biological processes, including embryonic development and response to pathogens. The mature miRNAs negatively modulate protein translation by binding to the 3ˋ-untranslated region (3ˋ-UTR) of target mRNAs.
MicroR-375 is expressed in GCs and oocytes and targets genes that regulate follicular growth proliferation, spread and apoptosis of cumulus cells (CCs).
Overexpression of miR-375 blocked the ability to proliferate, increased the apoptosis rate of cumulus cells in cows, and suppressed estradiol production and follicular development in porcine GCs.
MiR-375 was elucidated to repress cell proliferation and enhance the apoptosis in bovine CCs via regulation of bone morphogenetic protein type II receptor (BMPR2), highlighting its involvement in oocyte maturation. MiR-375 was preferentially detected in SBM samples of implanted blastocysts compared with blastocysts that failed to implant.
Previous studies found that miR-1305 promote cell proliferation, migration, and invasion in cervical cancer. The expression of miR-1305 was upregulated in epithelial ovarian carcinoma and that has miR-1305 regulates cell cycle and cell apoptosis. Overexpression of hsa-miR-1305 increases cell apoptosis, while its knockdown reduces the number of apoptotic cells.
Binding miR-1305 with Wnt2, and enhancing the Wnt/β-catenin pathway to promotes cell proliferation, migration, invasion. Components of the WNT signaling pathway have been demonstrated to impact reproductive functions including regulation of follicle maturation.
MiR-1305 was found to be upregulated in RIF. However, there is still no report linking miR-1305 to RIF.
The Janus kinases (JAK) are part of the tyrosine kinase group of enzymes of which four members have been identified: JAK1, JAK2, JAK3 and TYK2 (Tyrosine kinase 2). JAK2 links to the intracellular domain of many cytokine receptors for signal transduction. When cytokines bind to JAK2 receptors, the phosphorylation of JAK2 leads to the phosphorylation of other intracellular molecules, mainly through the JAK2-STAT3 pathway, which ultimately leads to gene transcription, It plays an important role in cytokine signal transduction and regulation of cell growth and gene expression.
In preimplantation embryos, STAT3 is constitutively active during fetal stage and shown to be important for embryonic development. Previous study showed that JAK2 regulated the microfilaments aggregation during the mouse oocyte maturation..
JAK2-mediated sodium/hydrogen exchange activation regulated acute cell volume changes in the late single-cell stage of mouse preimplantation embryos. Dysregulation of cell volume in early preimplantation embryos may lead to embryonic development arrest.
JAK/STAT pathway also among the most important signaling pathways of endometrial angiogenesis and the implantation of the embryo.
PTEN (encoding phosphatase and tensin homolog) is a tumor suppressor gene functions to control cell growth, differentiation, and survival by regulating every phase of the cell cycle, PTEN is crucial for mammal reproduction, in which it functions as a mediator of apoptosis in GCs.
Apoptosis is closely involved with most of reproductive processes, including folliculogenesis, follicle selection, and atresia. Apoptosis in GCs has been closely associated with follicular atresia, and was suggested to impact the ovarian reserve in women undergoing IVF treatment.
PTEN mRNA levels were significantly decreased in CCs surrounding mature oocytes compared with immature oocytes and were overexpressed of in poor responders. Failed IVF outcomes might be related to the high PTEN transcript levels in GCs.
Aim of the Research:
1. Investigate the expression levels of circ-0033392, miR-375, miR-1305, JAK2, and PTEN in follicular fluids of females candidate for IVF.
2. Correlate the expression levels of measured biomarkers to the pregnancy rate and live birth rate.
3. Correlate the expression levels of the measured biomarkers with the embryological outcome which is the oocyte maturity rate, fertilization rate, embryo cleavage rate and blastocyst formation rate and implantation rate.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
infertile females prior to IVF
females diagnosed with idiopathic or male factor infertility. Follicular fluid samples will be obtained from all females following ovarian stimulation. Mature oocytes will be collected 34-36 h after human chorionic gonadotropin injection. Clinical follow up after embryo transfer, if the outcome will be a positive pregnancy test or clinical pregnancy with a fetal heartbeat at ≥ 8 weeks, the follicular fluid samples will be classified into the pregnancy group (I). In the absence of pregnancy, the samples will be classified as non-pregnancy group (ӀӀ)
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Females undergo embryo transfer of blastocysts after intracytoplasmic sperm injection (ICSI) or conventional in vitro fertilization (IVF)
Exclusion Criteria
2. Women with risk factors or diseases that could influence oocyte quality, such as women with body mass index ≥35 kg/m2, a diagnosis of polycystic ovarian syndrome or endometriosis or diminished ovarian reserve.
18 Years
39 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lamia Ahmed
assisstant lecturer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Assuit University, Assuit, Egypt.
Asyut, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Abdel-Halim Ali Abdel-Halim, professor
Role: CONTACT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CircularRNA-microRNA-mRNA axis
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.